In 1985, AMKL was officially incorporated into the AML-M7 category of FAB (16), and in 2008, WHO formulated the precise diagnostic criteria for AMKL, that is, ≥20% of bone marrow original cells and >50% of bone marrow original cells are derived from megakaryocytes, or platelet-specific antigens, such as factor VII, CD41, CD42, and CD61, which could be detected through bone marrow puncture biopsy (17). Here, F7 is linked to acute megakaryoblastic leukemia.